• +1-646-491-9876
    • +91-20-67278686

    Search

    Calcitonin Gene Related Peptide Type 1 Receptor Pipeline Review H1 2017

    Calcitonin Gene Related Peptide Type 1 Receptor Pipeline Review H1 2017

    • Report Code ID: RW0001858702
    • Category Pharmaceuticals
    • No. of Pages 60
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H1 2017

    Summary

    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2017, outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2, 6 and 3 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders and Undisclosed which include indications Migraine, Inflammatory Pain, Dental Pain, Diabetic Neuropathy, Nerve Injury, Neuropathic Pain, Post-Operative Pain, Stable Angina and Unspecified.

    Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
    - The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
    Allergan Plc
    Amgen Inc
    Biohaven Pharmaceutical Holding Company Ltd
    Eli Lilly and Company
    Fortress Biotech Inc
    Merck & Co Inc
    Teva Pharmaceutical Industries Ltd
    Vertex Pharmaceuticals Inc
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
    A-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AA-71 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AFAP-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AGN-241689 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Atogepant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BHV-3500 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CGRP - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    erenumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-8825 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Rimegepant sulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize CALCRL for Migraine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit CGRP for Migraine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ubrogepant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
    Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
    Featured News & Press Releases
    Jun 08, 2017: Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society
    Jun 08, 2017: Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
    May 18, 2017: Amgen Submits Biologics License Application To The FDA For Erenumab
    May 18, 2017: Heptares to Receive US$5 Million Milestone Payment from Teva
    Nov 16, 2016: Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study
    Sep 28, 2016: Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study
    Sep 15, 2016: Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine
    Sep 15, 2016: Novartis announces new positive data showing AMG 334 significantly reduces monthly migraine days in chronic migraine vs placebo
    Sep 14, 2016: Amgen present erenumab at webcast call
    Jun 08, 2016: Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine
    Jun 19, 2015: Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine
    May 15, 2015: Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine
    May 11, 2015: Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Allergan Plc, H1 2017
    Pipeline by Amgen Inc, H1 2017
    Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2017
    Pipeline by Eli Lilly and Company, H1 2017
    Pipeline by Fortress Biotech Inc, H1 2017
    Pipeline by Merck & Co Inc, H1 2017
    Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
    Pipeline by Vertex Pharmaceuticals Inc, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Amgen Inc
    Biohaven Pharmaceutical Holding Company Ltd
    Eli Lilly and Company
    Fortress Biotech Inc
    Merck & Co Inc
    Teva Pharmaceutical Industries Ltd
    Vertex Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//calcitonin-gene-related-peptide-type-1-receptor-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//calcitonin-gene-related-peptide-type-1-receptor-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//calcitonin-gene-related-peptide-type-1-receptor-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments